Alumis Reports 68% PASI‑90 in Phase 3 Envudeucitinib Trial, Eyeing 2026 NDA

Why It Matters

The 68% PASI‑90 result positions envudeucitinib as a potential disruptor in a market dominated by biologics, offering patients an oral alternative with comparable efficacy. Early itch relief and scalp‑specific benefits could expand the drug’s appeal to patients who have struggled with existing oral therapies. A positive SLE readout would transform envudeucitinib from a single‑indication psoriasis drug into a multi‑indication immunology platform, enhancing Alumis’s valuation and providing a broader revenue base. Conversely, failure in SLE would concentrate risk on the psoriasis market, where competition from established biologics remains fierce.

Key Takeaways

• 68% of Phase 3 patients achieved PASI‑90 by week 24, surpassing the 53‑58% benchmark of deucravacitinib.
• PAS I‑100 rate reached 41%, approaching efficacy levels of IL‑17/IL‑23 biologics.
• Scalp psoriasis cleared or nearly cleared in ~75% of patients, a traditionally hard‑to‑treat site.
• Alumis holds $569.5 million in cash, extending runway to Q4 2027.
• NDA filing planned for Q4 2026; SLE Phase 2b readout expected Q3 2026.

Pulse Analysis

Alumis’s envudeucitinib data arrives at a pivotal moment for oral immunomodulators. The psoriasis market has been reluctant to adopt oral agents because of modest efficacy and delayed symptom relief. By delivering a PASI‑90 rate of 68% and early itch improvement, Alumis challenges the entrenched perception that only injectable biologics can achieve high skin clearance. This could accelerate a shift toward oral therapies, especially among patients who prioritize convenience and early quality‑of‑life gains.

From a competitive standpoint, the data narrows the performance gap with Bristol Myers Squibb’s deucravacitinib, which set the previous TYK2 standard. If regulators view the cross‑trial comparison favorably, Alumis may capture market share from both TYK2 competitors and biologics, forcing incumbents to reconsider pricing and combination strategies. The upcoming SLE readout is equally critical; a positive outcome would cement envudeucitinib as a versatile TYK2 inhibitor, potentially unlocking a multi‑billion‑dollar pipeline across autoimmune diseases.

Investors should monitor the Q3 2026 SLE data and the Q4 2026 NDA submission timeline. A smooth regulatory path could propel Alumis into a high‑growth trajectory, while any setbacks would likely compress the stock’s valuation and heighten the need for additional financing. Overall, the Phase 3 results signal a meaningful inflection point for oral JAK/TYK2 therapeutics and could reshape treatment algorithms in dermatology and beyond.